Evidence map›Paper›PMID 31614739›Full record

ReviewInternational journal of molecular sciences2019

PPARγ and Cognitive Performance.

Michele d'Angelo, Vanessa Castelli, Mariano Catanesi, Andrea Antonosante, Reyes Dominguez-Benot, Rodolfo Ippoliti, Elisabetta Benedetti, Annamaria Cimini

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Sex-specific role of microglia in ΔNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Michele d'AngeloDepartment of Life, Health and Environmental Sciences, University of L'Aquila, 67100 L'Aquila, Italy.ORCID 0000-0002-3693-840X
Vanessa CastelliDepartment of Life, Health and Environmental Sciences, University of L'Aquila, 67100 L'Aquila, Italy.ORCID 0000-0002-7005-3218
Mariano CatanesiDepartment of Life, Health and Environmental Sciences, University of L'Aquila, 67100 L'Aquila, Italy.ORCID 0000-0002-2310-5513
Andrea AntonosanteDepartment of Life, Health and Environmental Sciences, University of L'Aquila, 67100 L'Aquila, Italy.ORCID 0000-0003-4151-7121
Reyes Dominguez-BenotDepartment of Life, Health and Environmental Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
Rodolfo IppolitiDepartment of Life, Health and Environmental Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
Elisabetta BenedettiDepartment of Life, Health and Environmental Sciences, University of L'Aquila, 67100 L'Aquila, Italy.ORCID 0000-0002-6740-7724
Annamaria CiminiDepartment of Life, Health and Environmental Sciences, University of L'Aquila, 67100 L'Aquila, Italy. annamaria.cimini@univaq.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent findings have led to the discovery of many signaling pathways that link nuclear receptors with human conditions, including mental decline and neurodegenerative diseases. PPARγ agonists have been indicated as neuroprotective agents, supporting synaptic plasticity and neurite outgrowth. For these reasons, many PPARγ ligands have been proposed for the improvement of cognitive performance in different pathological conditions. In this review, the research on this issue is extensively discussed.

Indexed as

CognitionAnimalsAutistic DisorderCognition DisordersHumansParkinson DiseasePPAR gammaSchizophreniaPPAR gammaAlzheimer’s diseaseautismHuntingtonParkinson’s diseasePPAR gammaPPARγ agonistsschizophrenia

Identifiers

PMID31614739
PMCPMC6834178

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.